Posted by Michael Wonder on 14 May 2020
Japan OKs public insurance coverage for SMA drug Zolgensma
13 May 2020 - A panel that advises the health minister approved on Wednesday coverage for Novartis' spinal muscular atrophy drug Zolgensma under Japan's health insurance system.
Following the approval at a general meeting of the Central Insurance Medical Council, the drug will be priced at 167,077,222 yen, the highest level of any drug covered by public health insurance in Japan.
The insurance coverage is set to take effect from May 20.
